Aptuit secured its first integrated drug delivery contract from Danube Pharmaceuticals. Aptuit will provide the company with a full range of drug development services and employ five of its global facilities to develop and manufacture Danube’s investigational compound in support of upcoming Phase II trials.
This project will include a wide range of Aptuit’s services, including API process development, cGMP API delivery, clinical manufacture, analytical services, clinical packaging and labeling, and Qualified Person release.
The Danube project will utilize Aptuit’s teams and facilities in Harrisonville and Kansas City, Missouri; Bathgate and Riccarton, Scotland; and Deeside, Wales, and will be coordinated by a central Aptuit project manager responsible for the full integration of services.
Having recently completed its sixth major acquisition, Aptuit reports that it has established competencies in API development and manufacture, preclinical technologies, analytical chemistries, informatics and information management, clinical packaging and logistics, and industry-leading consulting expertise. To date, Aptuit has invested more than $30 million internally to align its global operations and has embarked on a further $100 million expansion program to increase capacity and add additional services.